Home
Search
Search Results
Previously Searched
3167 results found
Expand All
Apply All
3167 results found

BIO Finance & Tax Committee Meeting
August 3, 2023
The Committee concentrates on tax, financial services, securities, and accounting policies that impact member companies and biotech capital formation. This committee advises BIO staff about the impact of legislation and regulations affecting these policy matters and supports BIO’s engagement with Treasury, the SEC, and the IRS, as well as Congress and the Administration. For more information and to join the Committee, please contact Emily Berst (eberst@bio.org).
Read More

BIO Comments to FDA on Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products
Letters, Testimony & Comments  •  August 3, 2023
In response to the agency's request for information (Docket No. FDA-2023-N-0743-0002), BIO provides detailed comments.
Read More

Imaginative approaches to cancer
Good Day BIO Newsletter  •  August 3, 2023
We have profiles of three cancer innovators—and why it matters in the context of recent policy developments. Plus, the Pantheon Awards are accepting nominations until August 11 and NIH announced Dr. Fauci’s successor. (476 words, 2 minutes, 22 seconds)
Read More

340B needs reform, says BIO
Good Day BIO Newsletter  •  August 2, 2023
BIO recently submitted comments to the U.S. Senate on the 340B program—here’s what we said, plus a recap of a successful BIO Asia-Taiwan. (406 words, 2 minutes, 1 second)
Read More

BIO Comments on the NIH Technology Transfer Workshop
Food & Farm Innovation  •  Letters, Testimony & Comments  •  August 1, 2023
BIO provides detailed comments in advance of the July 31, 2023 NIH Workshop, “Transforming Discoveries into Products: Maximizing NIH’s Levers to Catalyze Technology Transfer.
Read More

Preserving the value of public/private partnerships
Good Day BIO Newsletter  •  August 1, 2023
Happy August. BIO’s Dr. Hans Sauer explains exactly who funds biotech R&D, and a tick-borne allergy is on the rise as temperatures change ticks’ habits. (653 words, 3 minutes, 15 seconds)
Read More

BIO Comment on EU Compulsory Licensing Legislation
Letters, Testimony & Comments  •  July 31, 2023

Dr. Ted Love on M&A, price controls
Good Day BIO Newsletter  •  July 31, 2023
BIO Chair Dr. Ted W. Love has a must-read op-ed on how recent policy actions would have kept patients from accessing his breakthrough sickle cell treatment. Speaking of policy, the EU has proposed new compulsory licensing rules—we have BIO’s take. (550 words, 2 minutes, 45 seconds)
Read More

BIO Statement to the Senate 340B Bipartisan Working Group on Safeguarding and Strengthening 340B
Letters, Testimony & Comments  •  July 28, 2023
In response to a Request for Information (RFI) from the Senate 340B Bipartisan Working Group, BIO submitted detailed comments on the current status of the program and suggestions for improvements.
Read More

How biotech can enhance national security
Good Day BIO Newsletter  •  July 28, 2023
Ending the week with the role of biotech in national security and curing hepatitis, plus more reading and listening for this hot summer weekend. (521 words, 2 minutes, 36 seconds)
Read More